Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

References

• LeeAYYLevineMNVenous thromboembolism and cancer: risks and outcomesCirculation200310723 Suppl 1I17I2112814981
   PubMed Web of Science ®Google Scholar
• SallahSWanJYNguyenNPVenous thrombosis in patients with solid tumors: determination of frequency and characteristicsThromb Haemost200287457557912008937
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPiccioliARecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood2002100103484348812393647
   PubMed Web of Science ®Google Scholar
• LymanGHKhoranaAAKudererNMVenous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201331172189220423669224
   PubMed Web of Science ®Google Scholar
• KahnSRLimWDunnASAmerican College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice GuidelinesChest2012141Suppl 2e195Se226S22315261
   PubMed Web of Science ®Google Scholar
• FargeDDebourdeauPBeckersMInternational clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerJ Thromb Haemost2013111567023217107
   PubMed Web of Science ®Google Scholar
• MandalàMFalangaARoilaFManagement of venous thromboembolism in cancer patients: ESMO clinical practice guidelinesAnn Oncol201122Suppl 6vi85vi9221908511
   PubMed Web of Science ®Google Scholar
• DeitcherSRKesslerCMMerliGRigasJRLyonsRMFareedJSecondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day periodClin Appl Thromb Hemost200612438939617000884
   PubMed Web of Science ®Google Scholar
• MeyerGMarjanovicZValckeJComparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled studyArch Intern Med2002162151729173512153376
   PubMed Web of Science ®Google Scholar
• HullRDPineoGFBrantRFLong-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerAm J Med2006119121062107217145251
   PubMed Web of Science ®Google Scholar
• LeeAYKamphuisenPWMeyerGTinzaparin vs. warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trialJAMA2015314767768626284719
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNBakerRILow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med2003349214615312853587
   PubMed Web of Science ®Google Scholar
• WoodruffSFeugèreGAbreuPJenFA post-hoc analysis of dalteparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairmentJ Thromb Thrombolysis201642449450427344439
   PubMed Web of Science ®Google Scholar
• DranitsarisGVincentMCrowtherMDalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysisPharmacoeconomics200624659360716761906
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technology in HealthGuidelines for the Economic Evaluation of Health Technologies3rd edOttawa, CanadaCanadian Agency for Drugs and Technology in Health2006 Available from: http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdfAccessed August 18, 2015
   Google Scholar
• Task Force from the International Society of Pharmacoeconomics and Outcomes Research2015 Available from: http://www.ispor.org/TaskForces/Presentation-22.pdfAccessed August 18, 2015
   Google Scholar
• GordoisAPosnettJBorrisLThe cost effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgeryJ Thromb Haemost20031102167217414521600
   PubMed Web of Science ®Google Scholar
• GuanellaRDucruetTJohriMEconomic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluationJ Thromb Haemost20119122397240521951970
   PubMed Web of Science ®Google Scholar
• DastaJFPilonDModySHDaily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapyThromb Res2015135230331025555319
   PubMed Web of Science ®Google Scholar
• MickischGGoreMEscudierBProcopioGWalzerSNuijtenMCosts of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinibBr J Cancer20101021808619920817
   PubMed Web of Science ®Google Scholar
• HullRDPineoGFRaskobGEThe economic impact of treating deep vein thrombosis with low molecular weight heparin: outcome of therapy and health economic aspectsHaemostasis199828Suppl 381610069757
   PubMedGoogle Scholar
• DranitsarisGKahnSStumpoCPharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patientsAm J Cardiovasc Drugs2004 20044532533315449974
   PubMedGoogle Scholar
• DrummondMFStoddartGLTorranceGWMethods for the Economic Evaluation of Health Care ProgramsOxford, EnglandOxford University Press2005
   Google Scholar
• TorranceGWUtility approach to measuring health-related quality of lifeJ Chron Dis19874065936003298297
   PubMedGoogle Scholar
• GafniAAlternatives to the QALY measure for economic evaluationsSupport Care Cancer1997521051119069609
   PubMed Web of Science ®Google Scholar
• FernandezMMHogueSPreblickRKwongJKReview of the cost of venous thromboembolismClinicoecon Outcomes Res2015745146226355805
   PubMed Web of Science ®Google Scholar
• DranitsarisGPapadopoulosGHealth technology assessment of cancer drugs in Canada, the United kingdom and Australia: should the United States take notice?Appl Health Econ Health Policy201513329130225274258
   PubMed Web of Science ®Google Scholar